MBX Biosciences, Inc. (NYSE:MBX) Director Purchases $468,844.74 in Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon purchased 47,502 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $9.87 per share, for a total transaction of $468,844.74. Following the transaction, the director now directly owns 3,205,930 shares in the company, valued at $31,642,529.10. This trade represents a 1.50 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

MBX Biosciences Stock Performance

NYSE MBX opened at $11.83 on Friday. The stock’s 50 day simple moving average is $14.05. MBX Biosciences, Inc. has a 12-month low of $8.63 and a 12-month high of $27.50.

Hedge Funds Weigh In On MBX Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP increased its position in MBX Biosciences by 17.1% during the 4th quarter. Woodline Partners LP now owns 608,721 shares of the company’s stock worth $11,219,000 after purchasing an additional 89,046 shares during the period. Parkman Healthcare Partners LLC acquired a new position in MBX Biosciences during the 4th quarter worth approximately $3,133,000. Nuveen Asset Management LLC acquired a new position in MBX Biosciences during the 4th quarter worth approximately $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in MBX Biosciences during the 4th quarter worth approximately $117,000. Finally, Deutsche Bank AG acquired a new position in MBX Biosciences during the 4th quarter worth approximately $80,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.